![Sohaib Mir](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sohaib Mir
Direktor/Vorstandsmitglied bei
Montis Biosciences BV
Profil
Sohaib Mir currently works at Pheno Therapeutics Ltd., as Director from 2022, Montis Biosciences BV, as Director from 2019, Maxion Therapeutics Ltd., as Director from 2023, and Lifearc Ventures, as Partner from 2025.
Dr. Mir also formerly worked at Exvastat Ltd., as Director from 2016 to 2019, Alsa Management Services Ltd, as Investment Director from 2019 to 2021, Cambridge Innovation Capital Ltd, as Principal from 2014 to 2019, and Perella Weinberg Partners, as Analyst from 2012 to 2014.
Dr. Mir received his graduate degree in 2012 from the University of Cambridge and graduate degree and doctorate degree from the University of Birmingham.
Aktive Positionen von Sohaib Mir
| Unternehmen | Position | Beginn |
|---|---|---|
Montis Biosciences BV
 Montis Biosciences BV BiotechnologyHealth Technology Develops immune-oncology therapeutics that targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors | Direktor/Vorstandsmitglied | 01.12.2019 |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that provides remyelinating therapy services | Direktor/Vorstandsmitglied | 05.12.2022 |
Lifearc Ventures
 Lifearc Ventures Investment ManagersFinance Lifearc Ventrues invests in companies located in the United Kingdom. The firm targets companies operating in the fields of innovative translational scientific research. It provides financing for seed and early stage capital requirements and makes follow-on investments. It also acts as co-investor. | Private Equity Investor | 01.10.2021 |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures protein therapeutics for cardiovascular, autoimmune and chronic disorders | Direktor/Vorstandsmitglied | 21.09.2023 |
Ehemalige bekannte Positionen von Sohaib Mir
| Unternehmen | Position | Ende |
|---|---|---|
Alsa Management Services Ltd
 Alsa Management Services Ltd Investment ManagersFinance ALSA Ventures invests in companies located in the United Kingdom. The firm focuses on sectors such as therapeutics and biotechnology. It participates in early stage capital transactions. | Private Equity Investor | 01.10.2021 |
Cambridge Innovation Capital Ltd
 Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital seeks investment opportunities in companies located in the United Kingdom. The firm focuses on technology and life science companies. It participates in seed, early and late stage capital transactions. The firm makes co-investments. | Private-Equity-Analyst | 01.09.2019 |
Exvastat Ltd.
 Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Operates as a preclinical-stage pharmaceutical company which develops a treatment for acute respiratory distress syndrome | Direktor/Vorstandsmitglied | 20.08.2019 |
| PERELLA WEINBERG PARTNERS | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Sohaib Mir
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
29
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Birmingham
 University of Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cambridge Innovation Capital Ltd
Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital seeks investment opportunities in companies located in the United Kingdom. The firm focuses on technology and life science companies. It participates in seed, early and late stage capital transactions. The firm makes co-investments. | Finance |
Exvastat Ltd.
Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Operates as a preclinical-stage pharmaceutical company which develops a treatment for acute respiratory distress syndrome | Health Technology |
Pheno Therapeutics Ltd.
Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that provides remyelinating therapy services | Commercial Services |
Montis Biosciences BV
Montis Biosciences BV BiotechnologyHealth Technology Develops immune-oncology therapeutics that targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors | Health Technology |
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance ALSA Ventures invests in companies located in the United Kingdom. The firm focuses on sectors such as therapeutics and biotechnology. It participates in early stage capital transactions. | Finance |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures protein therapeutics for cardiovascular, autoimmune and chronic disorders | Health Technology |
Perella Weinberg Partners
 Perella Weinberg Partners Investment ManagersFinance Provides financial and strategic advisory services | Finance |
Lifearc Ventures
Lifearc Ventures Investment ManagersFinance Lifearc Ventrues invests in companies located in the United Kingdom. The firm targets companies operating in the fields of innovative translational scientific research. It provides financing for seed and early stage capital requirements and makes follow-on investments. It also acts as co-investor. | Finance |
